Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II radioimmunotherapy with yttrium-90 ibritumomab tiuxetan as part of nonmyeloablative conditioning before allogeneic hematopoietic cell transplantation in advanced non-Hodgkin lymphoma
2005-002206-37Phase 2Completed
- Sponsor
- Universitätsklinikum Marburg, Klinik für Hämatologie, Onkologie und Immunologie
- Start
- Sep 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Universitätsklinikum Marburg, Klinik für Hämatologie, Onkologie und Immunologie. Primary endpoints: Treatment-related toxicity, Engraftment and 2 more. Started Sep 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-002206-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002206-37.